Clinical Trial Update: Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) [Phase 3]

View source ↗

Summary

Extension study update for idelalisib in chronic lymphocytic leukemia participants from a prior phase 3 trial; study terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2019-08-20